Abstract

FORMULATION DEVELOPMENT AND EVALUATION OF ORAL DISINTEGRATING TABLET OF CANDESARTAN CILEXETIL.

Lokesh Kumar*, Virendra Singh and Rakesh Kumar Meel

Abstract

Candesartan cilexetil is selective AT1 subtype angiotensin II receptor and it is used in treatment of hypertension, heart failure and myocardial infarction. The oral disintegrating tablets as recently developed drug delivery system. Candesartan cilexetil should be administrated orally once or twice daily for a total daily dose of 4 to 32 mg. In this investigation oral disintegrating tablet were prepared by using super disintegrating agent crospovidone, croscaremellose sodium, sodium starch glycolate in concentration 3%, 4%, 5%. Sweeteners and flavors were used to enhance the organoleptic properties of tablet. Tablets were prepared by direct compression technique. Formulated oral disintegrating tablets were evaluated for weight variation, friability, disintegration time, drug content, wetting time, water absorption ratio and in vitro drug release. The results show that the all formulations satisfied the limits of oral disintegrating tablet. The formula [F9] that contain 5% crospovidone as superdisintegrant shows the best results with a disintegrating time 31 sec, hardness 3.7 kg/cm2 and drug release rate 98.08% within 10 min.

Keywords: Candesartan cilexetil, oral disintegrating tablet, crospovidone.